Pyrazole Compounds Useful As Protein Kinase Inhibitors

Details for Australian Patent Application No. 2006201391 (hide)

Owner Vertex Pharmaceuticals Incorporated

Inventors Davies, Robert; Bebbington, David; Li, Pan; Golec, Julian

Agent Cullen & Co

Pub. Number AU-B-2006201391

Priority 60/257,887 21.12.00 US; 60/286,949 27.04.01 US; 60/232,795 15.09.00 US

Parent 2001290912

Filing date 4 April 2006

Wipo publication date 27 April 2006

Acceptance publication date 13 November 2008

International Classifications

C07D 403/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

A61K 31/497 (2006.01)

A61K 31/53 (2006.01) - having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

A61P 35/00 (2006.01) Antineoplastic agents

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 403/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 405/14 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 407/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group

C07D 409/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms

C07D 417/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

C07D 473/16 (2006.01) Heterocyclic compounds containing purine ring systems

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

C07D 491/04 (2006.01) Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or

C07D 493/04 (2006.01) Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system

C07D 495/04 (2006.01) Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms

C07D 498/04 (2006.01) Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms

C07D 513/04 (2006.01) Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or

C07D 521/00 (2006.01) Heterocyclic compounds containing unspecified hetero rings

Event Publications

27 April 2006 Application Open to Public Inspection

  Published as AU-B-2006201391

27 April 2006 Complete Application Filed

  Priority application(s): 60/257,887 21.12.00 US; 60/286,949 27.04.01 US; 60/232,795 15.09.00 US

11 May 2006 Amendment Made

  The nature of the amendment is: Delete priority details 60/257,887 21 Dec 2000 US, 60/286,949 27 Apr 2001 US and 60/232,795 15 Sep 2000 US 2006201392 Vertex Pharmaceuticals Incorporated The nature of the amendment is: Delete the priority details 60/232,956 16 Sep 2000 US 2006201396 Vertex Pharmaceuticals Incorporated The nature of the amendment is: Delete priority details 60/232,795 15 Sep 2000 US and 60/257,887 21 Dec 2000 US 2006201397 Vertex Pharmaceuticals Incorporated The nature of the amendment is: De

13 November 2008 Application Accepted

  Published as AU-B-2006201391

12 March 2009 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 19 Jan 2009. Address for service in Australia - Cullen & Co Level 26 239 George Street Brisbane QLD 4000

2 July 2009 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 19 Jan 2009

9 July 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006201392-Isoxazoles and Their Use as Inhibitors of Erk

2006201390-Method for predicting liver fibrosis and related pathologies